Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers BRNS RCUS SGMT SNDX
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers IPSC MIRM RPHM SGMT
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tickers SGMT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.